

Erratum to: Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area

A. Cortese¹ · G. Vita^{2,3} · M. Luigetti⁴ · M. Russo³ · G. Bisogni⁴ · M. Sabatelli⁴ · F. Manganelli⁵ · L. Santoro⁵ · T. Cavallaro⁶ · G. M. Fabrizi⁶ · A. Schenone⁷ · M. Grandis⁷ · C. Gemelli⁷ · A. Mauro⁸ · L. G. Pradotto⁸ · L. Gentile² · C. Stancanelli^{2,9} · A. Lozza¹ · S. Perlini¹⁰ · G. Piscosquito¹¹ · D. Calabrese¹¹ · A. Mazzeo² · L. Obici¹² · D. Pareyson¹¹

Published online: 20 April 2016
© Springer-Verlag Berlin Heidelberg 2016

Erratum to: J Neurol
DOI 10.1007/s00415-016-8064-9

Unfortunately, the online published article has errors in Fig. 1 (% in Fig. 1d 2/5 is 40 % and not 28 %). The original article has been corrected.

The correct Fig. 1 is given in the following page.

The online version of the original article can be found under doi:[10.1007/s00415-016-8064-9](https://doi.org/10.1007/s00415-016-8064-9).

✉ D. Pareyson
davide.pareyson@istituto-besta.it

- ¹ C. Mondino National Neurological Institute, IRCCS, Pavia, Italy
- ² Department of Neurosciences, University of Messina, Messina, Italy
- ³ NEMO SUD Center for Neuromuscular Disorders, Fondazione Aurora Onlus, Messina, Italy
- ⁴ Department of Geriatrics, Neurosciences and Orthopedics, Institute of Neurology, Catholic University of Sacred Heart, Rome, Italy
- ⁵ Department of Neurosciences, Reproductive and Odontostomatological Sciences, University Federico II of Naples, Naples, Italy
- ⁶ Department of Neurological, Neuropsychological, Morphological and Motor Sciences, University of Verona, Verona, Italy

- ⁷ Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics and Maternal Health Sciences, University of Genoa, Genoa, Italy
- ⁸ Division of Neurology and Neurorehabilitation, Ospedale San Giuseppe, Istituto Auxologico Italiano, IRCCS, Piancavallo, Verbania, Italy
- ⁹ Biomedical Department of Internal and Specialistic Medicine, University of Palermo, Palermo, Italy
- ¹⁰ Clinica Medica II, Department of Internal Medicine, Fondazione Policlinico IRCCS San Matteo, University of Pavia, Pavia, Italy
- ¹¹ Clinic of Central and Peripheral Degenerative Neuropathies Unit, Department of Clinical Neurosciences, IRCCS Foundation, “C. Besta” Neurological Institute, via Celoria 11, 20133 Milan, Italy
- ¹² Amyloidosis Research and Treatment Center, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy




Fig. 1 Changes of neurological function during Tafamidis treatment. **a** Change from baseline of NIS over 18 months of treatment in early (stage 1, $N = 21$) and late (stage 2 & 3, $N = 13$) stages of the disease. **b** Progression of neurological impairment in patients followed up over 36 months of treatment (note that patients with longer follow up had more severe disease due to inclusion of patients in stage 2–3 in the

early phases of the study). **c** Six-month change of NIS over 18 months of treatment ($N = 35$). **d** Percentage of responders (change of NIS from baseline $NIS-LL < 2$ points) over 36 months of treatment. $NIS-LL$ neuropathy impairment score, $NIS-LL$ NIS-lower limb, $F-U$ follow-up